A Phase 4 interventional study of Moxifloxacin (Avelox, BAY12-8039) and Amoxicillin/Clavulanate in Sinusitis and Bacterial Infections, sponsored by Bayer. Terminated at 34 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-11-07.
Sponsored by Bayer · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a clinical study organized to collect clinical data to better define the activity of some antimicrobials already marketed in Italy and in the rest of the world for the treatment of acute bacterial rhinosinusitis
256 studies on the registry are indexed under Sinusitis; 23 are open to participants now.
This study's enrollment of 293 is above the median of 60 across 196 interventional studies indexed under Sinusitis.
Browse Sinusitis studies →Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Moxifloxacin (Avelox, BAY12-8039) 400 mg tablets once daily (OD) for 7 days and amoxicillin/clavulanate 1000 mg matching placebo tablets three times daily (TID)for 10 days
Drug: Moxifloxacin (Avelox, BAY12-8039)
Amoxicillin/clavulanate 1000 mg tablets three times daily (TID) for 10 days and moxifloxacin 400 mg matching placebo tablets once daily (OD) for 7 days
Drug: Amoxicillin/Clavulanate
Patients will be administered daily a single moxifloxacin 400 mg tablet for 7 days
Drug pages: Amoxicillin · Clavulanic Acid
Patient will be administered daily Amoxicilline/Clavulanate 1000 mg tablets every 8 hours for 10 days
Number of Participants With Response (Per-protocol Population)
Number of patients in the population who met criteria pre-specified in the protocol whose clinical response 1-3 days after treatment was assessed by the investigator as "clinical cure"
Time frame: At 'Test-of-Cure', Day 1-3 after treatment
Number of Participants With Response (Intent-to-treat Population)
Number of patients in the population who received at least one dose of study medication whose clinical response 1-3 days after treatment was assessed by the investigator as "clinical cure"
Time frame: At 'Test-of-Cure', Day 1-3 after treatment
Number of Participants With Response (Per-protocol Population)
Number of patients in the population who met criteria pre-specified in the protocol whose clinical response 24-30 days after treatment was assessed by the investigator as "continued clinical cure"
Time frame: End of Follow-up, Day 24-30 after treatment
Number of Participants With Response (Microbiologically Valid Patients)
Bacteriological Efficacy Rate at the 'Test-of-Cure' visit, measured in patients defined as 'microbiologically valid'. A bacteriological success is an eradication without super- or reinfection or presumed eradication.
Time frame: At 'Test-of-Cure', Day 1-3 after treatment
Number of Participants With Response (Microbiologically Valid Patients)
Bacteriological Efficacy Rate at the End of Follow-up period, measured in patients defined as 'microbiologically valid'. A bacteriological success is an eradication without super- or reinfection or presumed eradication.
Time frame: End of Follow-up, Day 24-30 after treatment
Enrollment started on 13 Feb 2006 and the last study visit occurred on 20 Jan 2008. The study was conducted at 34 active otorhinolaryngology centers in Italy.
| Milestone | Moxifloxacin (Avelox, BAY12-8039) | Amoxicillin/Clavulanate |
|---|---|---|
| Started | 147 | 146 |
| Randomization | 147 | 146 |
| Treated with study medication | 145 | 142 |
| Test-of-cure visit | 123 | 126 |
| Completed | 123 | 126 |
| Not completed | 24 | 20 |
| Withdrew: Adverse event | 8 | 4 |
| Withdrew: Lost to follow-up | 5 | 3 |
| Withdrew: Withdrawal by subject | 11 | 12 |
| Withdrew: Other | 0 | 1 |
| Milestone | Moxifloxacin (Avelox, BAY12-8039) | Amoxicillin/Clavulanate |
|---|---|---|
| Started | 123 | 126 |
| Completed | 122 | 126 |
| Not completed | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
Number of patients in the population who met criteria pre-specified in the protocol whose clinical response 1-3 days after treatment was assessed by the investigator as "clinical cure"
| participants | Moxifloxacin (Avelox, BAY12-8039) | Amoxicillin/Clavulanate |
|---|---|---|
| Number of Participants With Response (Per-protocol Population) | 119 | 125 |
Number of patients in the population who received at least one dose of study medication whose clinical response 1-3 days after treatment was assessed by the investigator as "clinical cure"
| participants | Moxifloxacin (Avelox, BAY12-8039) | Amoxicillin/Clavulanate |
|---|---|---|
| Number of Participants With Response (Intent-to-treat Population) | 128 | 127 |
Number of patients in the population who met criteria pre-specified in the protocol whose clinical response 24-30 days after treatment was assessed by the investigator as "continued clinical cure"
| participants | Moxifloxacin (Avelox, BAY12-8039) | Amoxicillin/Clavulanate |
|---|---|---|
| Number of Participants With Response (Per-protocol Population) | 108 | 117 |
Bacteriological Efficacy Rate at the 'Test-of-Cure' visit, measured in patients defined as 'microbiologically valid'. A bacteriological success is an eradication without super- or reinfection or presumed eradication.
| Participants | Moxifloxacin (Avelox, BAY12-8039) | Amoxicillin/Clavulanate |
|---|---|---|
| Bacteriological success | 21 | 25 |
| Failure | 0 | 1 |
Bacteriological Efficacy Rate at the End of Follow-up period, measured in patients defined as 'microbiologically valid'. A bacteriological success is an eradication without super- or reinfection or presumed eradication.
| Participants | Moxifloxacin (Avelox, BAY12-8039) | Amoxicillin/Clavulanate |
|---|---|---|
| Bacteriological success | 19 | 23 |
| Failure | 0 | 0 |
| Missing / Indeterminate | 2 | 3 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Moxifloxacin (Avelox, BAY12-8039) | — | 1/145 (0.7%) | 0/145 (0%) |
| Amoxicillin/Clavulanate | — | 1/142 (0.7%) | 0/142 (0%) |
| Event | Moxifloxacin (Avelox, BAY12-8039) | Amoxicillin/Clavulanate |
|---|---|---|
| SinusitisInfections and infestations | 0/145 | 1/142 |
| Chest painGeneral disorders | 1/145 | 0/142 |
| Age, Continuous(years) | Moxifloxacin (Avelox, BAY12-8039) | Amoxicillin/Clavulanate | Total |
|---|---|---|---|
| Mean | 41.7 ± 13.2 | 39.7 ± 13.6 | 40.7 ± 13.4 |
| Age, Customized(participants) | Moxifloxacin (Avelox, BAY12-8039) | Amoxicillin/Clavulanate | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| >18 and <65 years | 133 | 132 | 265 |
| >=65 years | 12 | 10 | 22 |
| Sex: Female, Male(Participants) | Moxifloxacin (Avelox, BAY12-8039) | Amoxicillin/Clavulanate | Total |
|---|---|---|---|
| Female | 63 | 75 | 138 |
| Male | 82 | 67 | 149 |
The record gives a start of Feb 2006, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2009, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Moxifloxacin